Siltuximab

Research use only, not for human use.

Siltuximab（CNTO-328） is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.

Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.

——

Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model.Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model.Animal Model:Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells Dosage:10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg; 3 times per week Result:Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells.Repressed PY-STAT3 levels in H1650 cells.Inhibited the growth of tumors with H322 and CAF cells.Inhibited the growth of tumors with H1650 and CAF cells.Animal Model:Female NOD-SCID mice with MCF-7 tumor Dosage:20 mg/kg Administration:Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks Result:Blocked MCF-7 engraftment, induced regressions in 90% of tumors.

——

Apoptosis

IL Receptor

IL Receptor

——

——

541502-14-1

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years